Source 1review2008International Journal of Nanomedicine
Toolkit/liposomes
liposomes
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and phospholipids for liposomes
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Evaluate the promise and comparative potential of lipid nanoparticles, extracellular vesicles, and liposomes for hepatic drug or gene delivery in liver disease therapy.
Why it works: The review uses a systematic search and comparative analysis across preclinical and clinical studies to assess vesicle composition, targeting efficiency, payload capacity, therapeutic outcomes, and limitations across three nanovesicle platforms.
targeted hepatic deliveryreduction of off-target effectssystematic search of peer-reviewed studiescomparative analysis of preclinical and clinical research
Stages
- 1.systematic search of peer-reviewed studies(broad_screen)
This stage identifies the body of literature relevant to hepatic drug or gene delivery using the three nanovesicle platforms under review.
Selection: peer-reviewed studies in electronic databases focused on preclinical and clinical research investigating LNPs, EVs, and liposomes for hepatic drug or gene delivery
- 2.comparative analysis of included studies(secondary_characterization)
This stage compares the included nanovesicle platforms on delivery-relevant and translationally relevant properties.
Selection: analysis of vesicle composition, targeting efficiency, payload capacity, therapeutic outcomes, and reported limitations
Objective: Engineer and evaluate resveratrol nanoformulations that improve delivery performance while reducing safety risk.
Why it works: The review frames nanoencapsulation and formulation optimization as a way to address the physicochemical instability, poor permeability, and rapid metabolism that limit resveratrol efficacy.
nanoencapsulationtargeted deliverycontrolled or improved drug releasenanodelivery system selectionnanoformulation optimizationin vivo testing
Stages
- 1.Nanoformulation design and carrier selection(library_design)
The abstract identifies multiple carrier classes as promising approaches to improve resveratrol delivery performance.
Selection: Choose among nanodelivery system classes for resveratrol nanoencapsulation.
- 2.Formulation optimization(functional_characterization)
The review describes strategies to improve key formulation properties of existing nanoformulations.
- 3.In vivo safety-oriented testing across disease settings(in_vivo_validation)
The abstract explicitly states that in vivo testing is needed to avoid potential safety issues.
Objective: Develop extracellular-vesicle-based drug delivery systems that can realize the platform's therapeutic potential while addressing translation bottlenecks.
Why it works: The review frames EV development as requiring coordinated design and development steps rather than relying on carrier identity alone. It highlights loading, characterization, and manufacturing as critical to realizing EV potential as drug carriers.
loading methodsin-depth characterizationlarge-scale manufacturing
Stages
- 1.cargo loading method development(library_design)
The abstract identifies loading methods as a critical design and development step for utilizing extracellular vesicles as drug carriers.
Selection: Establish loading methods for extracellular vesicle drug carriers.
- 2.in-depth characterization(functional_characterization)
The abstract identifies in-depth characterization as a critical development step for EV drug carriers.
Selection: Characterize extracellular vesicle preparations in depth.
- 3.large-scale manufacturing(decision_gate)
The abstract identifies large-scale manufacturing as a critical development step and separately notes that clinical translation remains challenging.
Selection: Assess or develop large-scale manufacturing capability for extracellular-vesicle-based drug carriers.
Objective: Evaluate nanoparticle drug delivery systems for both therapeutic utility and formulation-specific hazards.
Why it works: The review argues that nanoparticle hazards differ from those of conventional matrices and that inhalation particle toxicology provides a useful framework for investigating these risks.
crossing biological barriersblood brain barrier transportcellular and subcellular accesscomposition-dependent tissue interaction and toxicitysafety evaluation informed by inhalation toxicology
Stages
- 1.Formulation selection and preparation(library_design)
The review states that many different substances are under investigation for preparing nanoparticles and that composition strongly affects biological interaction and toxicity.
Selection: Choose nanoparticle materials and formulation classes for drug delivery, including biological substances, phospholipids, polymers, and metal-containing nanoparticles.
- 2.Benefit-oriented biological assessment(functional_characterization)
The review highlights barrier crossing and intracellular access as key positive features of nanoparticles for drug delivery.
Selection: Assess whether nanosize provides useful delivery properties such as crossing biological barriers, brain access, and cellular entry.
- 3.Hazard and toxicology evaluation(confirmatory_validation)
The review emphasizes that nanoparticle carriers can impose risks beyond conventional matrices and that additional specific testing may be needed.
Selection: Evaluate formulation-specific hazards using particle toxicology concepts and determine whether standard pharmaceutical testing is sufficient.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Computational DesignTarget processes
manufacturingInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Source 3review2021Nature Nanotechnology
Source 4review2016Polymers
Source 5review2022Journal of Pharmaceutical Investigation
Source 6primary paper2025MED
Source 7review2026PMC
Source 8review2023Drug Delivery
Source 9primary paper2026MED
Source 10review2026MED
Source 11primary paper2025MED
Ranked Claims
These spatial engineering platforms are designed to reconfigure metabolic landscapes in cellular or cell-free contexts.
designed to reconfigure metabolic landscapes in cellular or cell-free contexts
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Comprehensive safety assessments remain a challenge for nanoparticle-based Huntington's disease therapies.
Nanoscale carriers are described as able to traverse the blood-brain barrier and enable direct delivery of treatment agents to regions affected by Huntington's disease.
The reviewed spatial engineering platforms include scaffolded compartments such as liposomes, DNA origami, polymersomes, and bacterial microcompartments, as well as scaffoldless assemblies such as membraneless organelles and coacervates.
This review systematically evaluates several spatial engineering platforms for biocatalytic process control-including scaffolded compartments (liposomes, DNA origami, polymersomes, and bacterial microcompartments) and scaffoldless assemblies (membraneless organelles and coacervates)...
Multifunctional vesicles in cancer treatment offer targeted drug delivery, reduced side effects, and improved drug stability.
highlighting the advantages they offer, such as targeted drug delivery, reduced side effects, and improved drug stability
Multifunctional vesicles used in cancer treatment include liposomes, polymersomes, extracellular vesicles, and hybrid vesicles.
This paper explores the various types of multifunctional vesicles utilized in cancer treatment, including non-biological vesicles such as liposomes and polymersomes, biological vesicles like extracellular vesicles (EVs), and hybrid vesicles that combine the benefits of both.
Multifunctional vesicles have potential pitfalls including stability issues, manufacturing complexity, and toxicity concerns.
we discuss the potential pitfalls associated with these vesicles, including stability issues, manufacturing complexity, and toxicity concerns
LNPs demonstrate strong efficiency in nucleic acid encapsulation and delivery and are supported by growing clinical translation.
The analysis indicates that LNPs demonstrate strong efficiency in nucleic acid encapsulation and delivery, supported by growing clinical translation.
EVs show promising biocompatibility and innate targeting to hepatic cells but face challenges in large-scale production and standardization.
EVs show promising biocompatibility and innate targeting to hepatic cells but face challenges in large-scale production and standardization.
Liposomes are versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
Liposomes remain versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
The review focuses on exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms as nanomedicine approaches for liver diseases.
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
Multiple nanodelivery system classes have shown great potential to improve the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Nanodelivery systems, such as liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, exosomes, macrophages, and red blood cells (RBCs) have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
The review discusses poor solubility and biocompatibility of photosensitive agents as motivating problems for lipid-based nanoparticle delivery systems.
This review covers lipid-based nanoparticles as platforms for photosensitive drug delivery systems.
The review states that extracellular vesicles have several advantages over conventional synthetic carriers for drug delivery.
Various studies suggest that extracellular vesicles have several advantages over conventional synthetic carriers, opening new frontiers for modern drug delivery.
The review compares the prospects of extracellular vesicles with those of well established liposomes.
We compare the prospects of extracellular vesicles with those of the well established liposomes.
Using extracellular vesicles to their full potential as drug carriers requires attention to loading methods, in-depth characterization, and large-scale manufacturing.
Here, we discuss the uniqueness of extracellular vesicles along with critical design and development steps required to utilize their full potential as drug carriers, including loading methods, in-depth characterization and large-scale manufacturing.
Clinical translation of extracellular-vesicle-based therapies remains challenging.
Despite extensive research, clinical translation of extracellular-vesicle-based therapies remains challenging.
The review specifically covers liposomes, self-assembly, layer-by-layer, and interfacial polymerization as preparation techniques for light-responsive carrier systems.
Nanoparticle size creates potential to cross biological barriers, including the blood brain barrier, and to access cells and subcellular compartments including the nucleus.
Nanoparticles are being used in drug delivery to reduce drug toxicity and side effects, but the carrier systems themselves can introduce patient risks beyond those of conventional delivery matrices.
The interaction of nanoparticle formulations with tissues and cells, and their potential toxicity, depend strongly on the actual composition of the formulation.
Lessons from particle toxicity in inhalation toxicology may be useful for evaluating the hazards of nanoparticle drug delivery formulations.
Current pharmaceutical safety requirements may detect most adverse effects of nanoparticle formulations but are not expected to detect all aspects of nanoparticle toxicology, so additional specific testing is probably needed.
Approval Evidence
11 sources16 linked approval claimsfirst-pass slug liposomes
The supplied web research summary lists liposomes as an explicit delivery component and notes support from a miR-22-3p therapeutic paper referencing liposome or nanoparticle-based delivery in TNBC models.
Source:
This review systematically evaluates several spatial engineering platforms for biocatalytic process control-including scaffolded compartments (liposomes, DNA origami, polymersomes, and bacterial microcompartments)...
Source:
These nano systems, including liposomes, dendrimers, polymeric nanoparticles, and solid lipid nanoparticles, offer significant potential by targeting and modulating intricate biochemical pathways involved in the progression of Huntington's disease.
Source:
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
Source:
including non-biological vesicles such as liposomes and polymersomes
Source:
This review aims to evaluate the promise and comparative potential of three key nanovesicle platforms-lipid nanoparticles (LNPs), extracellular vesicles (EVs) and liposomes-for drug and gene delivery in liver disease therapy.
Source:
Nanodelivery systems, such as liposomes ... have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Source:
The review title explicitly names lipid-based nanoparticles for photosensitive drug delivery systems, and the supplied summary states that lipid nanoparticle formats such as liposomes are emphasized.
Source:
We compare the prospects of extracellular vesicles with those of the well established liposomes.
Source:
A special focus is put on systems activated by wavelengths less harmful for living organisms ... as well as on different preparation techniques, namely liposomes, self-assembly, layer-by-layer, and interfacial polymerization.
Source:
A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and phospholipids for liposomes
Source:
application scopesupports
These spatial engineering platforms are designed to reconfigure metabolic landscapes in cellular or cell-free contexts.
designed to reconfigure metabolic landscapes in cellular or cell-free contexts
Source:
delivery modality recurrencesupports
Exosomes, nanoparticles, liposomes, aptamer-siRNA conjugates, and antisense oligonucleotides are presented in the supplied summary as recurring or relevant component classes for TNBC ncRNA therapeutics.
Source:
limitation summarysupports
Comprehensive safety assessments remain a challenge for nanoparticle-based Huntington's disease therapies.
Source:
mechanism summarysupports
Nanoscale carriers are described as able to traverse the blood-brain barrier and enable direct delivery of treatment agents to regions affected by Huntington's disease.
Source:
scope statementsupports
The reviewed spatial engineering platforms include scaffolded compartments such as liposomes, DNA origami, polymersomes, and bacterial microcompartments, as well as scaffoldless assemblies such as membraneless organelles and coacervates.
This review systematically evaluates several spatial engineering platforms for biocatalytic process control-including scaffolded compartments (liposomes, DNA origami, polymersomes, and bacterial microcompartments) and scaffoldless assemblies (membraneless organelles and coacervates)...
Source:
advantagesupports
Multifunctional vesicles in cancer treatment offer targeted drug delivery, reduced side effects, and improved drug stability.
highlighting the advantages they offer, such as targeted drug delivery, reduced side effects, and improved drug stability
Source:
application scopesupports
Multifunctional vesicles used in cancer treatment include liposomes, polymersomes, extracellular vesicles, and hybrid vesicles.
This paper explores the various types of multifunctional vesicles utilized in cancer treatment, including non-biological vesicles such as liposomes and polymersomes, biological vesicles like extracellular vesicles (EVs), and hybrid vesicles that combine the benefits of both.
Source:
limitationsupports
Multifunctional vesicles have potential pitfalls including stability issues, manufacturing complexity, and toxicity concerns.
we discuss the potential pitfalls associated with these vesicles, including stability issues, manufacturing complexity, and toxicity concerns
Source:
platform strength and limitationmixed
Liposomes are versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
Liposomes remain versatile and well-characterized platforms capable of carrying diverse therapeutic molecules, though rapid clearance can limit their efficacy.
Source:
scope statementsupports
The review focuses on exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms as nanomedicine approaches for liver diseases.
Here, we systematically review the latest advancements in nanomaterials for liver diseases, focusing on innovative nanocarriers such as exosomes, liposomes, microneedle technologies, biomimetic microfibers, and emerging platforms.
Source:
review summarysupports
Multiple nanodelivery system classes have shown great potential to improve the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Nanodelivery systems, such as liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, exosomes, macrophages, and red blood cells (RBCs) have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol.
Source:
problem statementsupports
The review discusses poor solubility and biocompatibility of photosensitive agents as motivating problems for lipid-based nanoparticle delivery systems.
Source:
review scopesupports
This review covers lipid-based nanoparticles as platforms for photosensitive drug delivery systems.
Source:
comparison scopeneutral
The review compares the prospects of extracellular vesicles with those of well established liposomes.
We compare the prospects of extracellular vesicles with those of the well established liposomes.
Source:
preparation method scopesupports
The review specifically covers liposomes, self-assembly, layer-by-layer, and interfacial polymerization as preparation techniques for light-responsive carrier systems.
Source:
composition dependent toxicitysupports
The interaction of nanoparticle formulations with tissues and cells, and their potential toxicity, depend strongly on the actual composition of the formulation.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.